SDEV Stablecoin Development Corp
$1.24 +4.20%
Healthcare · Pharmaceutical Preparations
Stablecoin Development Corp (SDEV) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $34 million. Shares last traded at $1.24, 45.1% below their 52-week high. Net profit margin is -6449.0%, below the peer median of -0.1%. Revenue grew 66.5% year over year.
Market Cap
$34M
Shares Out
27.1M
EPS (TTM)
$12.18
P/E Ratio
0.10
P/S Ratio
3.44
P/B Ratio
0.24
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.26
52-Week Low
$1.00
Volume
1,738
Avg Vol (3m)
6,886.868
Performance
1W
+1.64%
1M
-22.01%
3M
—
6M
—
YTD
-31.87%
1Y
—
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
48.14
SMA (50)
$1.38
SMA (200)
—
Price vs SMA50
-10.21%
Price vs SMA200
—
ATR (14)
$0.16
Financials
Revenue
$10M
Net Income
$-631M
Gross Margin
66.3%
Operating Margin
-86.3%
Net Margin
-6449.0%
Return on Equity
-454.4%
Return on Assets
-350.9%
Current Ratio
5.33
Debt / Equity
0.29
Revenue Growth (YoY)
+66.5%
Latest reported annual period ending 2024-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $3.33 | 2026-05-15 |
| Q3 2025 | $0.76 | 2025-11-07 |
| Q2 2025 | $1.01 | 2025-08-14 |
| Q1 2026 | $7.08 | 2026-05-15 |
| Q3 2025 | $-7.96 | 2025-11-07 |
| Q2 2025 | $-5.57 | 2025-08-14 |
Pharmaceutical Preparations peers
SDEV vs 14 industry peers (Pharmaceutical Preparations), by market cap.
P/S vs peers
3.44 / 3.54 med
-3% discount
Net margin vs peers
-6449.0% / -0.1% med
below median
1–14 of 14
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.